Search Results for "Topiramate Cr Pharmacokinetic"
Original Source: A Study to Evaluate the Pharmacokinetics of VI-0521 in Subjects With Hepatic Impairment
This study is designed to determine the effects of a single dose of the study medication in subjects with and without hepatic impairment. 18 to 24 subjects will participate by having multiple blood draws taken to measure the level of study medication in their blood over time.
Matching Channels
Generics Drugs - news, views, reports
A generic drug (generic drugs, short: generics) is a drug defined as "a drug product that is comparable to brand/reference listed drug product in dosage form, strength, route of administration,...
Matching News
Topiramate in pregnancy may boost oral clefts risk
NEW YORK (Reuters Health) - Pooled data suggest that first-trimester use of topiramate monotherapy is associated with a small increased risk of cleft lip and cleft palate in offspring.
Supernus soars on tentative ER topiramate approval
Supernus Pharmaceuticals Inc. (NASDAQ:SUPN) jumped $6.52 (114%) to $12.23 on Tuesday after FDA granted tentative approval of an NDA for Trokendi XR (formerly SPN-538) to treat epilepsy. Supernus said...
ScinoPharm to offer commercial manufacturing of topiramate API for VIVUS' Qsymia
ScinoPharm announced today that its Tainan, Taiwan Facility will provide commercial manufacturing of topiramate active pharmaceutical ingredient ("API") for VIVUS' Qsymia, a new drug for the treatment...
Phentermine/topiramate maintains weight loss long term
NEW YORK (Reuters Health) - Treatment with controlled-release (CR) phentermine/topiramate was associated with significant weight loss as well as improvements in cardiovascular risk factors in obes...
FDA approves once-daily phentermine and topiramate extended-release for weight management
FDA has approved once-daily phentermine and topiramate extended-release (Qsymia, Vivus) as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adu...
Results from a pharmacokinetic study...
Vivus planning $200 million note offering
Vivus Inc. (NASDAQ:VVUS) said it plans to raise $200 million through the sale of unsecured senior convertible notes due May 1, 2020. The company markets obesity drug Qsymia phentermine/topiramate in t...
Avanir Reports Positive Interim Data From Pharmacokinetic Trial With AVP-786
WASHINGTON (dpa-AFX) - Avanir Pharmaceuticals Inc. (AVNR) reported the completion of the first of a two-stage pharmacokinetic trial with AVP-786, a drug product containing a deuterium modified for...
Matching PubMed Articles
A rapid liquid chromatography coupled with ESI tandem mass spectrometry (LC-MS/MS) method was developed and validated for the quantification of topiramate in heparinized human plasma. The plasma sampl...
Effects of topiramate on diabetes mellitus induced by streptozotocin in rats.
Topiramate currently approved for marketing as antiepileptic drug also possesses anti-diabetic activity. The aim of this study was to determine the antidiabetic effect of topiramate in a rat model of...
Nephrolithiasis in topiramate users.
Topiramate is a neuromodulatory agent increasingly prescribed for a number of neurological and non-neurological indications. Topiramate-treated patients are at risk for nephrolithiasis due to hypocitr...
Perimenstrual migraines and their response to preventive therapy with topiramate.
Introduction: Preventive treatment with topiramate is effective for overall reduction of migraine frequency, but there are few data regarding its efficacy on perimenstrual migraines. To determine whet...
Efficacy and safety of topiramate on weight loss: a meta-analysis of randomized controlled trials.
Topiramate was associated with weight loss in clinical trials. We summarize the evidence on the efficacy and safety of topiramate in the treatment of overweight/obesity. The databases Medline, Embase,...
